HME Square has been selected for the 2026 'Innovation Premier 1000' in the Bio-health category.

This achievement recognizes our capabilities in developing non-invasive blood glucose monitoring technology and medical devices powered by AI-based photoacoustic technology.

We are currently preparing for the pivotal clinical trials of our portable non-invasive blood glucose monitor, while also developing a wearable continuous glucose monitor (CGM).

With this milestone, we will accelerate commercialization through ongoing R&D and clinical trials, growing into a global MedTech company.